Pharma Report on Uveitis – Pipeline Review, H2 2020

Source: https://www.researchbymarkets.com/report/uveitis-pipeline-review-h2-2020-645864.html

Uveitis – Pipeline Review, H2 2020

Summary

Uveitis – Pipeline Review, H2 2020, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Uveitis – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 9, 6, 1, 1, 43 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
– The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Aciont Inc
Active Biotech AB
Afecta Pharmaceuticals Inc
Akari Therapeutics Plc
Aldeyra Therapeutics Inc
Alpine Immune Sciences Inc
Alvotech ehf
Apidel SA
Apitope International NV
Bonac Corp
Chugai Pharmaceutical Co Ltd
Dobecure SL
E&B Technologies LLC
Elasmogen Ltd
Eleusis Ltd
Emerald Bioscience Inc
Enzo Biochem Inc
EyePoint Pharmaceuticals Inc
Eyevensys SAS
EyGen Ltd
F. Hoffmann-La Roche Ltd
Galapagos NV
HanAll Biopharma Co Ltd
HanAll Biopharma Co Ltd
Idogen AB
InSight Biopharmaceuticals Ltd
Kodiak Sciences Inc
Kubota Vision Inc
Kv1.3 Therapeutics
MetrioPharm AG
Mitotech SA
Naegis Pharmaceuticals Inc
NeuClone Pty Ltd
Novaliq GmbH
Novartis AG
Oculis SA
OKYO Pharma Ltd
OncoNOx ApS
ONL Therapeutics Inc
Orchid Pharma Ltd
OSE Immunotherapeutics
Palatin Technologies Inc
Panag Pharma Inc
Panoptes Pharma GesmbH
Pharmapraxis
Re-Pharm Ltd
Reven Pharmaceuticals Inc
RiniSight Inc
Ripple therapeutics Corp
Santen Pharmaceutical Co Ltd
SFA Therapeutics LLC
Sol-Gel Technologies Ltd
Sparrow Pharmaceuticals Inc
Tarsius Pharma Ltd
Tianjin Pharmaceuticals Group Co Ltd
Vyome Therapeutics Inc


For queries regarding this report: https://www.researchbymarkets.com/sample-request/645864

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.